BioCentury on BioBusiness,
Table: Follow-on performance
Back to the parent article
Monday, April 7, 2014
Sixty-one biotechs raised $4.7 billion in follow-ons
in 1Q14, doubling the $2.3 billion raised by 32 companies in 1Q13. Follow-ons
last quarter were down a median of 2% from their postmoney valuations, led by a
56% decline by Exelixis Inc. (NASDAQ:EXEL). The biotech's shares fell
39% on March 26 after an IDMC said the Phase III COMET-1 trial of Cometriq
cabozantinib for metastatic castration-resistant prostate cancer (CRPC) did not
meet criteria to support early unblinding.
Retrophin Inc. (NASDAQ:RTRX) is up 162% from
its January follow-on. The rare disease company surged in
February after acquiring Manchester Pharmaceuticals LLC for $62.5 million. (A)
Follow-ons of units consisting of stock and warrants are excluded from the
postmoney and percentage change calculations because the price per share was
not available; (B) Totals for postmoney and March 31 market values exclude unit
deals; (C) Median percentage change
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]